Filing Flows › Regeneron Pharmaceuticals (REGN) › Recalls, complaints & regulation
Regeneron Pharmaceuticals (REGN): recalls, clinical trials and Federal Register
Regeneron Pharmaceuticals (REGN) beyond its filings: 1 recall in the last 12 months (3 in five years, 0 Class I); 3 Federal Register documents in a year; 124 active clinical trials.
Latest recalls
- 2026-08-26 · FDA drug · Libtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), For Intravenous Infusion After Dilution, Single-Dose Vial, Rx only, Manufactured by: Regeneron Phar
- 2024-06-05 · FDA drug · EYLEA, (aflibercept) Injection, For Intravitreal injection, 2 mg (0.05mL of a 40mg/mL solution), Single-dose Pre-filled Glass Syringe, Rx only, Manufactured by:
- 2024-05-08 · FDA drug · EYLEA, (aflibercept) Injection, 2 mg (0.05mL of a 40mg/mL solution), Single-dose Pre-filled Syringe, Rx only, Manufactured by: Regeneron Pharmaceuticals, Inc.,
Regeneron Pharmaceuticals' latest quarter
Regeneron Pharmaceuticals, Q3 2026: revenue $5.1B (+36% year over year), operating margin 40.0%, net earnings $1.9B, operating cash flow $1.8B. The chart follows the revenue to costs, profit and cash.
Questions
Has Regeneron Pharmaceuticals had any recalls?
3 recalls on file over five years from the FDA, CPSC and NHTSA; 1 in the last 12 months.
How many clinical trials does Regeneron Pharmaceuticals have?
124 active studies on ClinicalTrials.gov, 39 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.